Bayer (FRA:BAYN) has been given a €102.00 ($121.43) target price by equities research analysts at Nord/LB in a research note issued to investors on Friday. The firm presently has a “neutral” rating on the healthcare company’s stock. Nord/LB’s price objective would indicate a potential downside of 2.53% from the company’s current price.
A number of other research analysts have also commented on the company. UBS set a €125.00 ($148.81) target price on Bayer and gave the company a “buy” rating in a research note on Tuesday, August 29th. S&P Global set a €126.00 ($150.00) target price on Bayer and gave the company a “buy” rating in a research note on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($155.95) target price on Bayer and gave the company a “buy” rating in a research note on Wednesday, November 29th. Independent Research set a €120.00 ($142.86) price target on Bayer and gave the company a “neutral” rating in a report on Wednesday, August 23rd. Finally, equinet set a €118.00 ($140.48) target price on Bayer and gave the company a “buy” rating in a research report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Bayer has an average rating of “Buy” and a consensus price target of €122.19 ($145.46).
Shares of Bayer (FRA:BAYN) traded up €0.50 ($0.60) during midday trading on Friday, reaching €104.65 ($124.58). 1,199,749 shares of the company’s stock were exchanged. Bayer has a 52 week low of €90.26 ($107.45) and a 52 week high of €123.82 ($147.40).
TRADEMARK VIOLATION WARNING: “Nord/LB Analysts Give Bayer (BAYN) a €102.00 Price Target” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://ledgergazette.com/2017/12/08/nordlb-analysts-give-bayer-bayn-a-102-00-price-target.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.